Save America’s Patent System; The New York Times, April 16, 2022

THE EDITORIAL BOARD, The New York Times; Save America’s Patent System

"Let the public participate. For too much of its history, the patent office has treated inventors and companies as its main customers while all but ignoring the people whose lives are affected by patenting decisions. That needs to change. Officials can start by appointing more public representatives to the patent office’s public advisory committee. Right now, six of the committee’s nine members are attorneys who represent commercial clients or private interests; only one works in public interest.

Officials should also establish a public advocate service similar to the one that exists at the Internal Revenue Service and should make a concerted effort to ramp up their public outreach. “The patent system has gotten so complicated that it’s impossible for anyone who’s not an inventor or a lawyer to penetrate it,” said Mr. Duan.

The patent system affects everyone, though. It’s time the people in charge of it recognize that."

Free Access to Intellectual Property is Crucial in Mitigating The COVID-19 Pandemic; News18, April 9, 2020

Simantini Dey, News18; Free Access to Intellectual Property is Crucial in Mitigating The COVID-19 Pandemic

"Furthermore, sharing intellectual property among members of academia is also important, so that the invention of a working vaccine can be accelerated, and more can be discovered about this potent virus. 

To ensure such co-operation, a group of scientists, lawyers, entrepreneurs and individuals have come together and started the 'Open COVID pledge' initiative. The organisations, institutions and universities who take the 'Open COVID Pledge' will voluntarily make the commitment of sharing their Intellectual Property related to COVID-19, thereby reducing information barrier. 

So far, Intel, Mozilla and Creative Commons have publically taken the Open COVID pledge. Harvard, MIT and Stanford have also agreed to this initiative. The University of Utah (Centre for Law and Biological Sciences), and Montreal Neurological Institute-Hospital are among some of the other institutions that have endorsed the pledge.

The current global healthcare crisis has brought to sharp focus the need to review patent laws of pharmaceutical products and how it should be reframed in case of a pandemic, or epidemic in future."

MSF Challenges Gilead Hepatitis C Patent In China; Intellectual Property Watch, June 19, 2018

Intellectual Property Watch; MSF Challenges Gilead Hepatitis C Patent In China

"According to the [Médecins Sans Frontières (MSF, Doctors Without Borders) press] release, “Gilead launched the sofosbuvir/velpatasvir combination at a price of US$51,000 for a 12-week treatment course in the United Kingdom, whereas the same treatment course is available for as low as $286 in India from generic manufacturers. In China, this combination was registered in May 2018, but Gilead has not yet announced its price.”